BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Up 68.0% in January

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 63,000 shares, a growth of 68.0% from the January 15th total of 37,500 shares. Based on an average daily volume of 67,300 shares, the short-interest ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a report on Monday, December 23rd.

Institutional Trading of BrainsWay

A number of large investors have recently bought and sold shares of the business. Good Life Advisors LLC boosted its position in shares of BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after purchasing an additional 22,080 shares in the last quarter. JPMorgan Chase & Co. lifted its position in BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after acquiring an additional 11,221 shares in the last quarter. Rhumbline Advisers lifted its position in BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after acquiring an additional 2,144 shares in the last quarter. ARK Investment Management LLC bought a new position in BrainsWay in the 4th quarter valued at about $1,656,000. Finally, Sei Investments Co. bought a new position in BrainsWay in the 4th quarter valued at about $149,000. 30.11% of the stock is currently owned by institutional investors and hedge funds.

BrainsWay Stock Up 0.1 %

BrainsWay stock traded up $0.01 during trading hours on Thursday, reaching $10.99. 31,627 shares of the company’s stock were exchanged, compared to its average volume of 60,102. The firm’s 50 day simple moving average is $9.98 and its 200 day simple moving average is $9.19. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.25. The firm has a market capitalization of $206.83 million, a PE ratio of 109.91 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The firm had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. During the same period last year, the business posted ($0.01) EPS. Analysts anticipate that BrainsWay will post 0.08 EPS for the current year.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.